medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.medsovet-5448Research ArticleСимпозиумыSymposiumПодходы к диагностике, лечению и профилактике обострений хронической обструктивной болезни легких. По материалам конгресса «Человек и лекарство» и Саммита пульмонологов – 2019Approaches to the diagnosis, treatment and prevention of exacerbations of chronic obstructive pulmonary disease. According to the materials of the Congress «Chelovek I lekarstvo» and the Summit of pulmonologists-2019https://orcid.org/0000-0003-0139-9773ЕвсютинаЮ. В.EvsyutinaYu. V.

101990,  Москва, Петроверигский пер., д. 10, стр. 3

evsyutina.yulia@gmail.comНациональный медицинский исследовательский центр профилактической медициныRussian Federation201908122019015112115Copyright © Евсютина Ю.В., 20192019Евсютина Ю.В.Evsyutina Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5448

Одной из главных тем, обсуждаемых в рамках XXVI Российского национального конгресса «Человек и лекарство» и Саммита пульмонологов – 2019, являлась хроническая обструктивная болезнь легких (ХОБЛ).

Хроническая обструктивная болезнь легких занимает лидирующую позицию в заболеваемости и смертности в мире. У многих пациентов ХОБЛ протекает с осложнениями, лечение которых представляет затруднения для клиницистов. В настоящее время разработан целый ряд эффективных мер профилактики обострений ХОБЛ, включая вакцинопрофилактику, отказ от курения, легочную реабилитацию. Больные ХОБЛ часто имеют сопутствующую патологию, что ассоциировано с неблагоприятным исходом, повышением частоты госпитализации и смерти. 

хроническая обструктивная болезнь легкихбронходилататорывакцинацияReferencesВОЗ. Хроническая обструктивная болезнь легких. https://www.who.int/respiratory/copd/burden/ru/.ВОЗ. Хроническая обструктивная болезнь легких. https://www.who.int/respiratory/copd/burden/ru/.Raherison C., Girodet P.O. Epidemiology of COPD. Eur Respir Rev. 2009;18(114):213-221.Raherison C., Girodet P.O. Epidemiology of COPD. Eur Respir Rev. 2009;18(114):213-221.Chuchalin A.G., Khaltaev N., Antonov N.S., et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD. 2014;12:963-974.Chuchalin A.G., Khaltaev N., Antonov N.S., et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD. 2014;12:963-974.Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2018.Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2018.Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;29:1224–1238.Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;29:1224–1238.Авдеев С.Н. Хроническая обструктивная болезнь легких: обострения. Пульмонология. 2013;3:5-19.Авдеев С.Н. Хроническая обструктивная болезнь легких: обострения. Пульмонология. 2013;3:5-19.Федеральные клинические рекомендации. Хроническая обструктивная болезнь легких. 2018.Федеральные клинические рекомендации. Хроническая обструктивная болезнь легких. 2018.Walters J.A.E., Tan D.J., White C.J., et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2014;(9):CD001288.Walters J.A.E., Tan D.J., White C.J., et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2014;(9):CD001288.Ram F.S., Rodriguez-Roisin R., GranadosNavarrete A., et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(2):CD004403.Ram F.S., Rodriguez-Roisin R., GranadosNavarrete A., et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(2):CD004403.Nouira S., Marghli S., Belghith M., et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001;358(9298):2020-2025.Nouira S., Marghli S., Belghith M., et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001;358(9298):2020-2025.Criner G.J., Bourbeau J., Diekemper R.L., et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147(4):894-942.Criner G.J., Bourbeau J., Diekemper R.L., et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147(4):894-942.Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(1):CD002733.Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(1):CD002733.Walters J.A., Smith S., Poole P., et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;(11):CD001390.Walters J.A., Smith S., Poole P., et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;(11):CD001390.Troosters T., Casaburi R., Gosselink R., Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:19-38.Troosters T., Casaburi R., Gosselink R., Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:19-38.Chen W., Thomas J., Sadatsafavi M., et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3:631–639.Chen W., Thomas J., Sadatsafavi M., et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3:631–639.Müllerova H., Agusti A., Erqou S., et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144:1163–1178.Müllerova H., Agusti A., Erqou S., et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144:1163–1178.Houben-Wilke S., Jörres R.A., Bals R., et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences–Comorbidities Network Study. Am J Respir Crit Care Med. 2017;195:189–197.Houben-Wilke S., Jörres R.A., Bals R., et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences–Comorbidities Network Study. Am J Respir Crit Care Med. 2017;195:189–197.Graat-Verboom L., Wouters E.F., Smeenk F.W., et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34:209–218.Graat-Verboom L., Wouters E.F., Smeenk F.W., et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34:209–218.Lacasse Y., Rousseau L., Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2001;21:80–86.Lacasse Y., Rousseau L., Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2001;21:80–86.Franssen F., Rochester С. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? European Respiratory Review. 2014;23:131-141.Franssen F., Rochester С. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? European Respiratory Review. 2014;23:131-141.Oelsner E.C., Carr J.J., Enright P.L., et al. Per cent emphysema is associated with respiratory and lung cancer mortality in the general population: a cohort study. Thorax. 2016;71(7):624-632.Oelsner E.C., Carr J.J., Enright P.L., et al. Per cent emphysema is associated with respiratory and lung cancer mortality in the general population: a cohort study. Thorax. 2016;71(7):624-632.Zulueta J.J., Wisnivesky J.P., Henschke C.I., et al. Emphysema scores predict death from COPD and lung cancer. Chest. 2012;141(5):1216-1223.Zulueta J.J., Wisnivesky J.P., Henschke C.I., et al. Emphysema scores predict death from COPD and lung cancer. Chest. 2012;141(5):1216-1223.Rutten E.P., Franssen F.M., Spruit M.A., et al. Anemia is associated with bone mineral density in chronic obstructive pulmonary disease. COPD. 2013;10:286–292.Rutten E.P., Franssen F.M., Spruit M.A., et al. Anemia is associated with bone mineral density in chronic obstructive pulmonary disease. COPD. 2013;10:286–292.Cebron Lipovec N., Beijers R.J., van den Borst B., Doehner W., Lainscak M., Schols A.M. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD. 2016;13(3):399-406.Cebron Lipovec N., Beijers R.J., van den Borst B., Doehner W., Lainscak M., Schols A.M. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD. 2016;13(3):399-406.Ingebrigtsen T.S., Marott J.L., Vestbo J., Nordestgaard B.G., Hallas J., Lange P. Gastroesophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology. 2015;20(1):101-107.Ingebrigtsen T.S., Marott J.L., Vestbo J., Nordestgaard B.G., Hallas J., Lange P. Gastroesophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology. 2015;20(1):101-107.Baumeler L., Papakonstantinou E., Milenkovic B., et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology. 2016;21(5):883-890.Baumeler L., Papakonstantinou E., Milenkovic B., et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology. 2016;21(5):883-890.

The authors declare that there are no conflicts of interest present.